The ocrevus market research report is one of a series of new reports that provides ocrevus market statistics, including ocrevus industry global market size, regional shares, competitors with a ocrevus market share, detailed ocrevus market segments, market trends and opportunities, and any further data you may need to thrive in the ocrevus industry. This ocrevus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to rising prevalence of multiple sclerosis disease, rising demand for immunomodulators stems, increasing new product approvals, growing demand for personalized medicines, increasing government initiatives. Major trends in the forecast period include facility expansion, investment In research and development, strategic collabration, technological advancements, focus on product launch.
The growing prevalence of multiple sclerosis (MS) is expected to drive the growth of the Ocrevus market. MS is a chronic autoimmune disorder that affects the central nervous system, where the immune system attacks the protective myelin sheath of nerve fibers. The rise in MS cases is attributed to a mix of genetic, environmental, and lifestyle factors, such as better diagnostic methods, increased awareness, and changes in diet and urban living conditions. Ocrevus is used to treat MS by targeting and depleting CD20-positive B-cells, which contribute to the immune system's damaging effects in MS. This helps reduce disease activity, slow progression, and manage symptoms. According to the MS Society UK, as of May 2024, over 150,000 people in the UK are living with MS, with a 15% increase in prevalence in England, and significant rises in Scotland, Northern Ireland, and Wales. This growing number of MS cases is expected to drive demand for Ocrevus.
The increasing emphasis on personalized medicine is also expected to boost the Ocrevus market. Personalized medicine involves tailoring treatment plans to individual patients based on their genetic makeup, enabling healthcare providers to make more informed and effective treatment decisions. This approach is gaining traction due to its potential to improve treatment outcomes, reduce side effects, and meet the demand for customized healthcare solutions. Personalized medicine’s growing prominence supports Ocrevus by enhancing its targeted treatment for MS, improving patient outcomes, and reinforcing its position as a preferred therapy. According to the Personalized Medicine Coalition, 34% of new drug approvals by the U.S. Food and Drug Administration (FDA) in 2022 were for personalized treatments, a trend that has remained consistent for the past eight years. As personalized medicine continues to advance, it is expected to drive further growth in the Ocrevus market.
A significant trend in the Ocrevus market is the role of regulatory approvals in driving innovation. Drug approval is the process by which regulatory authorities, such as the FDA, assess the safety, efficacy, and quality of a drug before granting it approval for public use. In September 2024, Genentech Inc. announced that the FDA had approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This new formulation of Ocrevus is the first subcutaneous injection that can be administered twice a year, taking approximately 10 minutes per session. The approval of Ocrevus Zunovo provides patients with more treatment options and offers healthcare providers greater flexibility in tailoring care to meet individual patient needs.
The key company operating in the ocrevus market is F. Hoffmann-La Roche Ltd.
North America was the largest region in the ocrevus market in 2024. The regions covered in ocrevus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ocrevus market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Ocrevus is a prescription monoclonal antibody used to treat relapsing forms of multiple sclerosis (RMS), including relapsing-remitting MS, active secondary progressive MS, and primary progressive MS (PPMS). It works by targeting and depleting CD20-positive B-cells, which play a role in the immune-mediated damage to nerve cells in MS.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Ocrevus is primarily indicated for relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). RRMS is a type of multiple sclerosis marked by distinct episodes of neurological symptoms followed by recovery periods. The medication is available in both liquid and tablet or capsule forms and can be administered via oral or injectable routes. It is commonly used in hospitals, retail pharmacies, and online pharmacies.
The ocrevus market consists of sales of monoclonal antibodies, cancer therapies, infusion delivery systems and research and development tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising prevalence of multiple sclerosis disease, rising demand for immunomodulators stems, increasing new product approvals, growing demand for personalized medicines, increasing government initiatives. Major trends in the forecast period include facility expansion, investment In research and development, strategic collabration, technological advancements, focus on product launch.
The growing prevalence of multiple sclerosis (MS) is expected to drive the growth of the Ocrevus market. MS is a chronic autoimmune disorder that affects the central nervous system, where the immune system attacks the protective myelin sheath of nerve fibers. The rise in MS cases is attributed to a mix of genetic, environmental, and lifestyle factors, such as better diagnostic methods, increased awareness, and changes in diet and urban living conditions. Ocrevus is used to treat MS by targeting and depleting CD20-positive B-cells, which contribute to the immune system's damaging effects in MS. This helps reduce disease activity, slow progression, and manage symptoms. According to the MS Society UK, as of May 2024, over 150,000 people in the UK are living with MS, with a 15% increase in prevalence in England, and significant rises in Scotland, Northern Ireland, and Wales. This growing number of MS cases is expected to drive demand for Ocrevus.
The increasing emphasis on personalized medicine is also expected to boost the Ocrevus market. Personalized medicine involves tailoring treatment plans to individual patients based on their genetic makeup, enabling healthcare providers to make more informed and effective treatment decisions. This approach is gaining traction due to its potential to improve treatment outcomes, reduce side effects, and meet the demand for customized healthcare solutions. Personalized medicine’s growing prominence supports Ocrevus by enhancing its targeted treatment for MS, improving patient outcomes, and reinforcing its position as a preferred therapy. According to the Personalized Medicine Coalition, 34% of new drug approvals by the U.S. Food and Drug Administration (FDA) in 2022 were for personalized treatments, a trend that has remained consistent for the past eight years. As personalized medicine continues to advance, it is expected to drive further growth in the Ocrevus market.
A significant trend in the Ocrevus market is the role of regulatory approvals in driving innovation. Drug approval is the process by which regulatory authorities, such as the FDA, assess the safety, efficacy, and quality of a drug before granting it approval for public use. In September 2024, Genentech Inc. announced that the FDA had approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This new formulation of Ocrevus is the first subcutaneous injection that can be administered twice a year, taking approximately 10 minutes per session. The approval of Ocrevus Zunovo provides patients with more treatment options and offers healthcare providers greater flexibility in tailoring care to meet individual patient needs.
The key company operating in the ocrevus market is F. Hoffmann-La Roche Ltd.
North America was the largest region in the ocrevus market in 2024. The regions covered in ocrevus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ocrevus market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Ocrevus is a prescription monoclonal antibody used to treat relapsing forms of multiple sclerosis (RMS), including relapsing-remitting MS, active secondary progressive MS, and primary progressive MS (PPMS). It works by targeting and depleting CD20-positive B-cells, which play a role in the immune-mediated damage to nerve cells in MS.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Ocrevus is primarily indicated for relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). RRMS is a type of multiple sclerosis marked by distinct episodes of neurological symptoms followed by recovery periods. The medication is available in both liquid and tablet or capsule forms and can be administered via oral or injectable routes. It is commonly used in hospitals, retail pharmacies, and online pharmacies.
The ocrevus market consists of sales of monoclonal antibodies, cancer therapies, infusion delivery systems and research and development tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Ocrevus Market Characteristics4. Ocrevus Market Trends And Strategies5. Ocrevus Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Ocrevus Pricing Analysis & Forecasts30. Global Ocrevus Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Ocrevus Market32. Recent Developments In The Ocrevus Market
3. Ocrevus Market Biologic Drug Characteristics
6. Global Ocrevus Growth Analysis And Strategic Analysis Framework
8. Ocrevus Market Segmentation
9. Global Ocrevus Epidemiology Of Clinical Indications
10. Ocrevus Market Regional And Country Analysis
11. Asia-Pacific Ocrevus Market
12. China Ocrevus Market
13. India Ocrevus Market
14. Japan Ocrevus Market
15. Australia Ocrevus Market
16. South Korea Ocrevus Market
17. Western Europe Ocrevus Market
18. UK Ocrevus Market
19. Germany Ocrevus Market
20. France Ocrevus Market
21. Eastern Europe Ocrevus Market
22. North America Ocrevus Market
23. USA Ocrevus Market
24. Canada Ocrevus Market
25. South America Ocrevus Market
26. Middle East Ocrevus Market
27. Africa Ocrevus Market
28. Ocrevus Market Competitive Landscape And Company Profiles
29. Global Ocrevus Market Pipeline Analysis
33. Ocrevus Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Ocrevus Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on ocrevus market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ocrevus ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ocrevus market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Clinical Indications: Relapsing-Remitting Multiple Sclerosis; Primary Progressive Multiple Sclerosis2) By Formulation: Liquid Formulations; Tablet Or Capsule Formulation
3) By Route Of Administration: Oral; Injectable
4) By End User: Hospitals; Retail Pharmacies; Online Pharmacies
Key Companies Profiled: F. Hoffmann-La Roche Ltd.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
